Aging and Cancer, EarlyView.Aging‐associated physiological and molecular alterations pose significant challenges in cancer management among India's elderly. Limited geriatric oncology expertise, financial constraints, and inadequate specialized care exacerbate disparities. Strategic expansion of insurance coverage, integration of palliative care, and infrastructural advancements ...
Nihanthy D. Sreenath +3 more
wiley +1 more source
Risk-benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score-weighted study in Japan. [PDF]
J Antimicrob ChemotherHashimoto Y, Inoue N, Tani T, Imai S.
europepmc +1 more source
Exercise physiology and diabetes: The risk-benefit profile
, 2005 Hyun-Shik Son
openalex +1 more source
Cutaneous Melanoma Drives Metabolic Changes in the Aged Bone Marrow Immune Microenvironment
Aging and Cancer, EarlyView.Melanoma, the deadliest form of skin cancer, increasingly affects older adults. Our study reveals that melanoma induces changes in iron and lipid levels in the bone marrow, impacting immune cell populations and increasing susceptibility to ferroptosis.
Alexis E. Carey +12 more
wiley +1 more source
Chauhan Weighted Trajectory Analysis of Combined Efficacy and Safety Outcomes for Risk-Benefit Analysis. [PDF]
Pharm StatChauhan U, Mackey D, Mackey JR.
europepmc +1 more source
The Aging Blood: Cellular Origins, Circulating Drivers, and Therapeutic Potential
Aging and Cancer, EarlyView.As a conduit linking all organs, the blood system both reflects and actively drives systemic aging. This review highlights how circulating pro‐aging and antiaging factors and age‐associated hematopoietic stem cell dysfunction contribute to immunosenescence and multi‐organ decline, positioning the hematopoietic system as a target for aging intervention.
Hanqing He, Jianwei Wang
wiley +1 more source
How external stimuli drive physicians' value co-creation behavior in online health communities: the mediating role of risk-benefit perceptions and moderating role of digital competency. [PDF]
Front Public HealthYao Y, Cao J, Wang J, Zhong Y, Feng M.
europepmc +1 more source
Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors. [PDF]
Rheumatology (Oxford), 2023 Hazlewood GS.
europepmc +1 more source
Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment [PDF]
, 2014 Holland C. Detke +3 more
openalex +1 more source